作者
Jared C Nesvet, Katie A Antilla, Danielle S Pancirer, Alexander X Lozano, Jordan S Preiss, Weijie Ma, Aihua Fu, Seung-Min Park, Sanjiv S Gambhir, Alice C Fan, Joel W Neal, Sukhmani K Padda, Millie Das, Tianhong Li, Heather A Wakelee, Shan X Wang
发表日期
2021/3/1
期刊
Clinical chemistry
卷号
67
期号
3
页码范围
534-542
出版商
Oxford University Press
简介
Background
Liquid biopsy circulating tumor DNA (ctDNA) mutational analysis holds great promises for precision medicine targeted therapy and more effective cancer management. However, its wide adoption is hampered by high cost and long turnaround time of sequencing assays, or by inadequate analytical sensitivity of existing portable nucleic acid tests to mutant allelic fraction in ctDNA.
Methods
We developed a ctDNA Epidermal Growth Factor Receptor (EGFR) mutational assay using giant magnetoresistive (GMR) nanosensors. This assay was validated in 36 plasma samples of non-small cell lung cancer patients with known EGFR mutations. We assessed therapy response through follow-up blood draws, determined concordance between the GMR assay and radiographic response, and ascertained progression-free survival of patients.
Results
The …
学术搜索中的文章
JC Nesvet, KA Antilla, DS Pancirer, AX Lozano… - Clinical chemistry, 2021